Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges (Record no. 97)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 05087nam a22005655i 4500 |
001 - CONTROL NUMBER | |
control field | 978-3-031-24355-4 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250526092116.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 230327s2023 sz | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 9783031243554 |
-- | 978-3-031-24355-4 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1007/978-3-031-24355-4 |
Source of number or code | doi |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
Classification number | QR46 |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | MMFM |
Source | bicssc |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | MED052000 |
Source | bisacsh |
072 #7 - SUBJECT CATEGORY CODE | |
Subject category code | MKFM |
Source | thema |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
Classification number | 616.9041 |
Edition number | 23 |
245 10 - TITLE STATEMENT | |
Title | Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges |
Medium | [electronic resource] : |
Remainder of title | Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis / |
Statement of responsibility, etc. | edited by Myron Christodoulides. |
250 ## - EDITION STATEMENT | |
Edition statement | 1st ed. 2023. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Place of production, publication, distribution, manufacture | Cham : |
Name of producer, publisher, distributor, manufacturer | Springer International Publishing : |
-- | Imprint: Springer, |
Date of production, publication, distribution, manufacture, or copyright notice | 2023. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | VI, 344 p. 28 illus., 27 illus. in color. |
Other physical details | online resource. |
336 ## - CONTENT TYPE | |
Content type term | text |
Content type code | txt |
Source | rdacontent |
337 ## - MEDIA TYPE | |
Media type term | computer |
Media type code | c |
Source | rdamedia |
338 ## - CARRIER TYPE | |
Carrier type term | online resource |
Carrier type code | cr |
Source | rdacarrier |
347 ## - DIGITAL FILE CHARACTERISTICS | |
File type | text file |
Encoding format | |
Source | rda |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Preface by Prof Myron Christodoulides, University of Southampton, UK.-1. Introduction chapter on the VALIDATE network -- (Prof Helen McShane, Director Oxford NIHR Biomedical Research Centre, University of Oxford, UK and Samantha Vermaak, The Jenner Institute Laboratories, Oxford, UK) -- Part I: Leprosy -- 2. Leprosy challenges to vaccine developers -- (Dr Hua Wang, University of Glasgow, UK) -- 3. Leprosy vaccine development -- (Dr Khushboo Borah, University of Surrey, UK) -- Part II: Tuberculosis -- 4. Biomarkers in tuberculosis vaccine development -- (Dr Kenneth Akwue, University of the Witwatersrand, Johannesburg, South Africa) -- 5. Tuberculosis correlates of protection (Dr Rachel Tanner, The Jenner Institute Laboratories, Oxford, UK), -- Animal models for tuberculosis (Dr. Hao Li, China Agricultural University, Beijing, China) -- 7. BCG vaccination -- (Dr Hazel Morrison, The Jenner Institute Laboratories, Oxford, UK) -- 8. Vaccination strategies for Buruli ulcer disease (Dr Rachel Simmonds, University of Surrey, UK) -- 9. Fermentation in vaccine development (BCG) (Dr. Joanna Bacon, Public Health England, UK Government, London, UK) -- Part III: Leishmaniasis: 10. Human leishmaniasis vaccination -- (Dr Ali Bordbar, Institute Pasteur of Iran, Tehran, Iran) -- 11. Aspects of human leishmaniasis vaccine use -- (Dr Olayinka Osuolale, Elizade University, Ilara-Mokin, Nigeria) -- 12. Human challenge model for developing leishmaniasis vaccines (Prof Paul Kaye, University of York, UK) -- 13. Canine leishmaniasis vaccines -- (Prof Eduardo Coelho, Federal University of Minas Gerais, Belo Horizonte, Brazil and Prof Myron Christodoulides, University of Southampton, UK) -- Part IV: Melioidosis -- 14. Vaccines for melioidosis (Prof Chiranjay Mukhopadhyay, Kasturba Medical College, Manipal, India) -- 15. West Africa burden of disease (Dr Tukur Ismail, Zamfara State Primary Healthcare Board, Gusau, Nigeria). |
506 0# - RESTRICTIONS ON ACCESS NOTE | |
Terms governing access | Open Access |
520 ## - SUMMARY, ETC. | |
Summary, etc. | This book reviews successes and (remaining) challenges in vaccine development for the selected Neglected Tropical Diseases (NTD) of Leprosy, Leishmaniasis, Meliodoisis and Tuberculosis, which are a continuous burden for millions of people in affected areas worldwide. Written by frontline researchers, the volume deep-dives into different vaccine strategies, provides biotechnological background information and also tackles animal models in NTD therapeutics research. By bringing together state-of-the-art expert knowledge, the book contributes to the aim of ultimately ending the epidemics of neglected tropical diseases, complying with UN Sustainable Development Goal 3, Health and Well-Being.The volume highlights the activities of the research network VALIDATE (VAccine deveLopment for complex Intracellular neglecteD pAThogEns), funded by the Medical Research Council in the UK. The four NTDs discussed in the book were selected as these are in the focus of VALIDATE’s research. The book targets scientists and clinicians working on NTDs, as well as all readers with a background in biomedicine and interest in vaccine development. This is an open access book. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Medical microbiology. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Vaccines |
General subdivision | Biotechnology. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Biomaterials. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Immunology. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Biotechnology. |
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Medical Microbiology. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Biomaterials-Vaccines. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Applied Immunology. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Biotechnology. |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Christodoulides, Myron. |
Relator term | editor. |
Relationship | edt |
-- | http://id.loc.gov/vocabulary/relators/edt |
710 2# - ADDED ENTRY--CORPORATE NAME | |
Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
773 0# - HOST ITEM ENTRY | |
Title | Springer Nature eBook |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
Relationship information | Printed edition: |
International Standard Book Number | 9783031243547 |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
Relationship information | Printed edition: |
International Standard Book Number | 9783031243561 |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
Relationship information | Printed edition: |
International Standard Book Number | 9783031243578 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1007/978-3-031-24355-4">https://doi.org/10.1007/978-3-031-24355-4</a> |
912 ## - | |
-- | ZDB-2-SBL |
912 ## - | |
-- | ZDB-2-SXB |
912 ## - | |
-- | ZDB-2-SOB |
No items available.